Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-Line Advanced Her2/Neu Positive Gastric and Gastroesophageal Junction Cancer

Celularity Inc. announced the US FDA has cleared its Investigational New Drug application for the use of CYNK-101 in combination with standard chemotherapy, trastuzumab and pembrolizumab in patients with first-line locally advanced unresectable or metastatic HER2/neu positive gastric or gastroesophageal junction adenocarcinoma.